Please wait a moment while we redirect you.
Paul Geevarghese, COO and Co-Founder of 9amHealth, stated in the news release announcing the partnernship, "We're not only lowering the cost of medications, we're also connecting members to real, human care: specialists in obesity and diabetes, clinical pharmacists, and ongoing nutritional support with registered dietitiansall from the comfort of home." Adding to that thought, Alex Oshmyansky, CEO of Mark Cuban Cost Plus Drug Company, said, "At Cost Plus Drugs, our commitment to transparent drug pricing has always been unwavering, and with clinical leaders in obesity like 9amHealth, we are dedicated to providing affordable and accessible healthcare solutions for patients with cardiometabolic conditions." What We Don't Know
Active Ingredient Semaglutide (Introductory GLP-1 Agonist) Total Strength per Vial Calibrated for 0.25mg and 0.5mg initial delivery Dose Classification Starter Phase & Early Titration Step 1 Primary Manufacturer Glenmark Pharmaceuticals Ltd Therapeutic Class Incretin Mimetic / Antidiabetic / Anti-Obesity Administration Route Subcutaneous Injection (Weekly calibrated dose) Supply Format 1 Multi-dose Vial / Pen System
With alli on your side, you can get a jumpstart on your diet
Paying through an employer-sponsored plan Most Americans get their health insurance through an employer
/assets/images/provider/photos/2775905.jpeg)
